{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:48:55Z","timestamp":1770522535025,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T00:00:00Z","timestamp":1244592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The significance of having had a suboptimal response during imatinib therapy among 281 patients with CML treated with standard\u2010dose (n = 73) or high\u2010dose (n = 208) imatinib was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Rates of suboptimal response at 6, 12, and 18 months were 4%, 8%, and 40%, respectively, and were not influenced by Sokal risk score. Patients with a suboptimal response at 6 months had a significantly lower probability of eventually achieving a complete cytogenetic response (CCyR) compared with those with an optimal response (30% vs 97%; <jats:italic>P<\/jats:italic> &lt; .001), and their event\u2010free survival (EFS) and transformation\u2010free survival (TFS) were found to be similar to those with criteria for failure at this time point. Suboptimal response at 12 months defined a group with a similar TFS as those with optimal response, but with worse EFS. In contrast, patients with a suboptimal response at 18 months had outcomes that were similar to those patients with an optimal response. A multivariate analysis confirmed the significance of response category after adjusting for pretreatment characteristics and imatinib dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The results of the current study suggested that suboptimal response was a heterogeneous category, and some patients had an outcome that mirrored that of patients with failed therapy. Interventions aimed at improving this outcome are required. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24418","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T10:03:09Z","timestamp":1244628189000},"page":"3709-3718","source":"Crossref","is-referenced-by-count":75,"title":["Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long\u2010term outcome of patients with early chronic myeloid leukemia in chronic phase"],"prefix":"10.1002","volume":"115","author":[{"given":"Yesid","family":"Alvarado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"15a","DOI":"10.1182\/blood.V110.11.25.25","article-title":"IRIS 6\u2010year follow\u2010up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"110","author":"Hochhaus A","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"issue":"18","key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2006.24.18_suppl.6506","article-title":"Long\u2010term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML\u2010CP): the 5\u2010year update from the IRIS study","volume":"24","author":"Druker B","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0545"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3800"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"626a","DOI":"10.1182\/blood.V108.11.2207.2207","article-title":"Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): a randomized trial of frontline high\u2010dose (HS) imatinib mesylate (IM) with or without pegylated\u2010interferon (PEG\u2010IFN) and GM\u2010CSF","volume":"108","author":"Quintas\u2010Cardama A","year":"2006","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non\u2010parametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1965","journal-title":"J Am Stat Assoc."},{"key":"e_1_2_6_12_2","volume-title":"Statistical Methods","author":"Snedecor G","year":"1980"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0025"},{"issue":"16","key":"e_1_2_6_15_2","first-page":"564s","article-title":"High\u2010dose imatinib in patients with previously untreated chronic myeloid leukemia in early chronic phase: preliminary results of a multicenter community based trial","volume":"23","author":"Cortes J","year":"2005","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_16_2","first-page":"31","article-title":"Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase","volume":"102","author":"Hughes T","year":"2003","journal-title":"Blood."},{"key":"e_1_2_6_17_2","first-page":"106","article-title":"Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML Working Party in intermediate Sokal risk patients and status\u2010of\u2010the\u2010art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients","author":"Rosti G","year":"2005","journal-title":"Blood."},{"key":"e_1_2_6_18_2","first-page":"110","article-title":"Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high\u2010dose imatinib","author":"Jain N","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_19_2","first-page":"110","article-title":"Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)\u2010positive chronic myelogenous leukemia in early chronic phase (CML\u2010CP)","author":"Cortes J","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_20_2","first-page":"110","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP)","author":"Cortes J","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_21_2","first-page":"112","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","author":"Marin D","year":"2008","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:15:44Z","timestamp":1760303744000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2009,8,15]]}},"alternative-id":["10.1002\/cncr.24418"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24418","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}